CLOs on the Move

Astellas Pharma

www.astellas.us

 
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.astellas.us
  • 1 Astellas Way
    Northbrook, IL USA 60062
  • Phone: 800.888.7704

Executives

Name Title Contact Details
Michael Mayes
 Executive Director, Anti-Bribery and Anti-Corruption, Third Party and Distributor Compliance Lead Profile

Similar Companies

Redox Pharmaceutical

Redox Pharmaceutical Corp. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Windgap Medical

Windgap Medical is developing health care products that meet the demands of your lifestyle. Our first product will improve the quality of life for patients living with severe allergies.

NEW Health Programs Association

NEW Health provides high quality health care services for all residents within the communities we serve. We offer a sliding fee discount for health services to those who qualify.   We believe that all people deserve...

Oterra

Oterra is the worlds largest natural food color manufacturer, providing naturally sourced colors for the food, beverage, dietary supplements, and pet food industry.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.